A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

BACKGROUND Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. METHODS We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. RESULTS Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and in the psychotherapy group, as compared with 73 percent in the combined-treatment group. (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). CONCLUSIONS Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone.

[1]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[2]  P. Lewinsohn,et al.  A behavioral approach to depression. , 1974 .

[3]  S. Hollon,et al.  6 – Cognitive Therapy of Depression1 , 1979 .

[4]  G. Klerman,et al.  Interpersonal psychotherapy of depression , 1984 .

[5]  J. P. Mccullough.  Cognitive-behavioral analysis system of psychotherapy: an interactional treatment approach for dysthymic disorder. , 1984, Psychiatry.

[6]  H. Conte,et al.  Combined psychotherapy and pharmacotherapy for depression. A systematic analysis of the evidence. , 1986, Archives of general psychiatry.

[7]  D. Blazer,et al.  The economic burden of depression. , 1986, General hospital psychiatry.

[8]  J. Fawcett,et al.  Clinical management--imipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program. , 1987, Psychopharmacology bulletin.

[9]  M. Weissman,et al.  The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. , 1988, The American journal of psychiatry.

[10]  J. Sweeney,et al.  Imipramine treatment for chronic depression. , 1988, Archives of general psychiatry.

[11]  J. P. Mccullough.  Psychotherapy for Dysthymia: A Naturalistic Study of Ten Patients , 1991, The Journal of nervous and mental disease.

[12]  H. Akiskal,et al.  The importance of measures of affective temperaments in genetic studies of mood disorders. , 1992, Journal of psychiatric research.

[13]  K. Wells,et al.  The course of depression in adult outpatients. Results from the Medical Outcomes Study. , 1992, Archives of general psychiatry.

[14]  E. Berndt,et al.  The economic burden of depression in 1990. , 1993, The Journal of clinical psychiatry.

[15]  Chronic depression. , 1993, Hospital & community psychiatry.

[16]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[17]  J. Markowitz.  Psychotherapy of dysthymia. , 1994, The American journal of psychiatry.

[18]  C. Sherbourne,et al.  Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. , 1995, Archives of general psychiatry.

[19]  M. Keller,et al.  Summary of the DSM-IV mood disorders field trial and issue overview. , 1996, The Psychiatric clinics of North America.

[20]  J. Markowitz,et al.  Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. , 1996, Archives of general psychiatry.

[21]  M. Fava,et al.  A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. , 1996, Archives of general psychiatry.

[22]  M. Paulus,et al.  The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. , 1997, Journal of affective disorders.

[23]  J. Markowitz,et al.  The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. , 1998, The Journal of clinical psychiatry.

[24]  J. Schwartz,et al.  Thirty-month naturalistic follow-up study of early-onset dysthymic disorder: course, diagnostic stability, and prediction of outcome. , 1998, Journal of abnormal psychology.

[25]  H. Conte,et al.  What Works for Whom? A Critical Review of Psychotherapy Research , 1998 .

[26]  J. Markowitz,et al.  The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. , 1998, The Journal of clinical psychiatry.

[27]  M. Versiani.  Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. , 1998, Journal of affective disorders.

[28]  M. Thase,et al.  Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. , 1998, JAMA.

[29]  J. Markowitz,et al.  The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. , 1998, The Journal of clinical psychiatry.

[30]  M. Trivedi,et al.  Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. , 1999, International clinical psychopharmacology.

[31]  J. Scott,et al.  Treatment of chronic depression. , 2000, The New England journal of medicine.

[32]  A. Rush,et al.  Psychotherapies for Depressive Disorders: A Review , 2001 .

[33]  J. Claiborn.  Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy , 2001 .